Sae Jung Na1, Hye Lim Park2, Joo Hyun O2, Sung Yong Lee1, Kyo Young Song3, Sung Hoon Kim4. 1. Department of Radiology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2. Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 3. Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 4. Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea sghn@catholic.ac.kr.
Abstract
BACKGROUND: Epstein-Barr virus-associated gastric cancer (EBVaGC) is one of the four molecular subtypes of gastric cancer, as defined by the classification recently proposed by The Cancer Genome Atlas. We evaluated the correlation between EBV positivity and 18F-fluorodeoxyglucose (18F-FDG) uptake by positron emission tomography/computed tomography (PET/CT) in patients with gastric cancer. MATERIALS AND METHODS: We retrospectively enrolled patients with gastric cancer who underwent pretreatment 18F-FDG PET/CT and subsequent surgical resection, and then were diagnosed with advanced gastric cancer (pathologic stage ≥T2 with any N stage). Maximum standardized uptake values (SUVmax) of gastric cancer were measured by pretreatment 18F-FDG PET/CT. EBV sequences were detected by in situ hybridization (ISH) techniques. We analyzed the correlation between EBV positivity, clinicopathologic features and metabolic activity of the primary tumor. RESULTS: A total of 205 patients were included and 15 (7.3%) patients were identified as having EBV-positive gastric cancer. Age, gender, tumor location, and histological type showed no significant differences between EBV-positive and negative groups. EBV-positive cancer is significantly more frequent in the higher-metabolic-tumor group than in the lower one (p=0.032). The mean SUVmax of gastric cancers showed significant differences between EBV-positive and negative groups (9.9±4.2 vs. 7.0±4.8, p=0.026). CONCLUSION: The infection status of EBV was significantly related to the 18F-FDG uptake of primary tumors in patients with advanced gastric cancer. Copyright
BACKGROUND:Epstein-Barr virus-associated gastric cancer (EBVaGC) is one of the four molecular subtypes of gastric cancer, as defined by the classification recently proposed by The Cancer Genome Atlas. We evaluated the correlation between EBV positivity and 18F-fluorodeoxyglucose (18F-FDG) uptake by positron emission tomography/computed tomography (PET/CT) in patients with gastric cancer. MATERIALS AND METHODS: We retrospectively enrolled patients with gastric cancer who underwent pretreatment 18F-FDG PET/CT and subsequent surgical resection, and then were diagnosed with advanced gastric cancer (pathologic stage ≥T2 with any N stage). Maximum standardized uptake values (SUVmax) of gastric cancer were measured by pretreatment 18F-FDG PET/CT. EBV sequences were detected by in situ hybridization (ISH) techniques. We analyzed the correlation between EBV positivity, clinicopathologic features and metabolic activity of the primary tumor. RESULTS: A total of 205 patients were included and 15 (7.3%) patients were identified as having EBV-positive gastric cancer. Age, gender, tumor location, and histological type showed no significant differences between EBV-positive and negative groups. EBV-positive cancer is significantly more frequent in the higher-metabolic-tumor group than in the lower one (p=0.032). The mean SUVmax of gastric cancers showed significant differences between EBV-positive and negative groups (9.9±4.2 vs. 7.0±4.8, p=0.026). CONCLUSION: The infection status of EBV was significantly related to the 18F-FDG uptake of primary tumors in patients with advanced gastric cancer. Copyright
Authors: K Kuzushima; S Nakamura; T Nakamura; Y Yamamura; N Yokoyama; M Fujita; T Kiyono; T Tsurumi Journal: J Clin Invest Date: 1999-07 Impact factor: 14.808
Authors: Jun Zhang; Lin Jia; Weitao Lin; Yim Ling Yip; Kwok Wai Lo; Victoria Ming Yi Lau; Dandan Zhu; Chi Man Tsang; Yuan Zhou; Wen Deng; Hong Lok Lung; Maria Li Lung; Lai Man Cheung; Sai Wah Tsao Journal: J Virol Date: 2017-02-28 Impact factor: 5.103
Authors: M C Camargo; G Murphy; C Koriyama; R M Pfeiffer; W H Kim; R Herrera-Goepfert; A H Corvalan; E Carrascal; A Abdirad; M Anwar; Z Hao; J Kattoor; E Yoshiwara-Wakabayashi; Y Eizuru; C S Rabkin; S Akiba Journal: Br J Cancer Date: 2011-06-07 Impact factor: 7.640
Authors: M Constanza Camargo; Woo-Ho Kim; Anna Maria Chiaravalli; Kyoung-Mee Kim; Alejandro H Corvalan; Keitaro Matsuo; Jun Yu; Joseph J Y Sung; Roberto Herrera-Goepfert; Fernando Meneses-Gonzalez; Yuko Kijima; Shoji Natsugoe; Linda M Liao; Jolanta Lissowska; Sung Kim; Nan Hu; Carlos A Gonzalez; Yashushi Yatabe; Chihaya Koriyama; Stephen M Hewitt; Suminori Akiba; Margaret L Gulley; Philip R Taylor; Charles S Rabkin Journal: Gut Date: 2013-04-12 Impact factor: 23.059